Please upgrade your browser.
In metastatic renal cell cancer (mRCC) patients treated with targeted therapy, baseline hyponatremia is associated with poorer overall survival (OS), time to treatment failure (TTF), and disease control rate (DCR), according to a study published in European Urology.
Sorafenat is the generic alternative to Bayer's Nexavar, and is used to treat a type of kidney cancer called advanced renal cell carcinoma as well as liver cancer.
Thousands of seriously ill cancer patients could be denied treatment under changes to the way drugs are funded...
Enrolling in a clinical trial has been difficult because Mikaela’s past treatment and need for corticosteroids to control brain swelling are criteria that exclude her from most Phase 2 and Phase 3 trials.
Available on Kidney Cancer Radio, as a PDF download, a Kindle book, in paperback, and on YouTube.
The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth...
Rates of renal mass biopsy (RMB) have been historically low in patients with kidney cancer, but are steadily rising, shows an analysis of Medicare data.
Results show BNC105 utility in patients with advanced disease
Raman molecular imaging was evaluated as a tool for differentiating between kidney tumors which are sometimes confused using conventional histopathological methods.
Tyrosine kinase inhibitor sorafenib decreases (111)In-girentuximab uptake in patients with clear cell renal cell carcinoma
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC).
|Powered by NeonCRM|